On the other hand, dual blockade therapies with angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs), while showing albuminuria improvement, do not suppress cardiovascular event onset and increase the risk of hyperkalemia and acute kidney injury23). This evidence concerns the gene ACE and Hyperkalemia.